← Leaderboards
Niloy Jewel Samadder
University Of Utah
$916,042
Attributed
$4,265,571
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2017–25$2.5M$1.9M$1.3M$625K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,265,571 · 3
By mechanism
U01$3,417,451 · 1
R01$445,446 · 1
R21$402,674 · 1
Top collaborators
- Daniel David Buchanan3 shared
- Steven Gallinger3 shared
- Mark A Jenkins3 shared
- Amanda Irene Phipps3 shared
- Stephanie L. Schmit3 shared
- Loic Le Marchand2 shared
- Deborah Wood Neklason2 shared
- John Kisiel1 shared
Most similar at University Of Utah
Same institution · by research overlap
- Kathleen H Mooney$23,401,107
- Yelena Ping Wu$6,313,886
- Randall Walter Burt$9,014,360
- Daniel Chavez-Yenter$276,934
- Deborah Wood Neklason$1,195,749
Others in their field
Other Emerging Leaders on “Malignant Neoplasms”
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
- Leonard Freedmand · Leidos Biomedical Research, Inc.$108,968,336
- Beverly Hayes · Leidos Biomedical Research, Inc.$98,336,166
- Martha Hering · Westat, Inc.$57,098,843
Research focus
Malignant NeoplasmsCessation Of LifeReportingSamplingColorectalColorectal CancerScreening For CancerCohortSitePreventivePersonsRisk FactorsScienceScreeningPharmaceutical PreparationsBiobankMethylationMutationInnovationBloodPopulation BasedParticipantResearch PersonnelSpecimen
Grant awards (6)
Colon Cancer Family Registry Cohort$1,639,442
U01 · FY2025 · CA
Multi-cancer Early Detection$445,446
R01 · FY2025 · CA
Colon Cancer Family Registry Cohort$158,520
U01 · FY2025 · CA
Colon Cancer Family Registry Cohort$1,619,489
U01 · FY2024 · CA
Metabolomic Strategies to Identify Biomarkers of Chemoprevention in FAP Patients$170,447
R21 · FY2018 · CA
Metabolomic Strategies to Identify Biomarkers of Chemoprevention in FAP Patients$232,227
R21 · FY2017 · CA